InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 [Yahoo! Finance]
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome [Yahoo! Finance]
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome